1. Home
  2. LYEL vs PRE Comparison

LYEL vs PRE Comparison

Compare LYEL & PRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

HOLD

Current Price

$13.01

Market Cap

320.1M

Sector

Health Care

ML Signal

HOLD

Logo Prenetics Global Limited

PRE

Prenetics Global Limited

HOLD

Current Price

$19.40

Market Cap

337.6M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
LYEL
PRE
Founded
2018
2014
Country
United States
Hong Kong
Employees
N/A
98
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Laboratory Analytical Instruments
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
320.1M
337.6M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
LYEL
PRE
Price
$13.01
$19.40
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
2
Target Price
$30.60
$30.50
AVG Volume (30 Days)
135.4K
257.3K
Earning Date
05-13-2026
06-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$36,000.00
N/A
Revenue This Year
N/A
$108.69
Revenue Next Year
$8,712.13
$58.68
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.49
$7.18
52 Week High
$45.00
$23.63

Technical Indicators

Market Signals
Indicator
LYEL
PRE
Relative Strength Index (RSI) 39.11 50.33
Support Level $12.00 $17.44
Resistance Level $13.88 $21.81
Average True Range (ATR) 1.05 1.47
MACD 0.18 -0.17
Stochastic Oscillator 54.44 35.12

Price Performance

Historical Comparison
LYEL
PRE

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

About PRE Prenetics Global Limited

Prenetics Global Ltd is a health sciences company dedicated to advancing consumer health. The consumer initiative is led by IM8, one of the world's fastest-growing supplement brands; Europa, one of the sports distribution companies in the USA; and CircleDNA, a direct-to-consumer DNA testing company. As the first consumer healthcare company to establish a Bitcoin treasury with its initial approximately $20 million Bitcoin purchase and board-approved comprehensive Bitcoin plan of action, Prenetics is pioneering the intersection of healthcare innovation and digital asset adoption.

Share on Social Networks: